Section Arrow
Quote
XERS.NASDAQ
- Xeris Biopharma Holdings
Quotes are at least 15-min delayed:2026/06/25 07:46 EDT
Pre Market
Last
 7.53
+0.13 (+1.76%)
Bid
7.4
Ask
7.51
High 7.68 
Low 6.78 
Volume 217.31K 
Regular Hours (Closed)
Last
 7.4
+0.2 (+2.78%)
Day High 
7.505 
Prev. Close
7.2 
1-M High
7.3 
Volume 
1.74M 
Bid
7.4
Ask
7.51
Day Low
7.2796 
Open
7.28 
1-M Low
5.81 
Market Cap 
1.24B 
Currency 美元 
P/E 102.86 
%Yield -- 
10-SMA 6.87 
20-SMA 6.51 
50-SMA 6.32 
52-W High 10.08 
52-W Low 4.52 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.07/0.28
Enterprise Value
1.49B
Balance Sheet
Book Value Per Share
0.08
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
291.85M
Operating Revenue Per Share
0.78
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health32.7-0.26-0.79%-- 
Pre Market 32.95 +0.25 +0.76%
ESPREsperion Therapeutics3.15-0.01-0.32%-- 
Pre Market 3.16 +0.01 +0.32%
HLNHaleon plc9.23+0.28+3.13%18.32PE
Pre Market 9.2218 -0.0082 -0.09%
VTRSViatris15.93+0.18+1.14%-- 
Pre Market 15.93 0 0.00%
BCRXBioCryst Pharmaceuticals10+0.69+7.41%-- 
Pre Market 10.0753 +0.0753 +0.75%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.